PMC10034280_01
Patient's thumbs (a) before treatment with bimekizumab and (b) 8 weeks after
initiation of bimekizumab.
10.1177_2050313X231160937-fig1.jpg
PMC10034280_01_10.1177_2050313X231160937-fig1.jpg
fig1-2050313X231160937
He reported an excellent response and no adverse effects within the first week of bimekizumab treatment, and both thumbnails had regrown normally after 2 months (Figure 1).